Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases (Q33736294)

29 July 2017

1 reference

title

Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases (English)

1 reference

29 July 2017

1 reference

J A Barman Balfour

1 reference

29 July 2017

R H Foster

series ordinal

1 reference

29 July 2017

publication date

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

553-578

1 reference

Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo

29 July 2017

cites work

1 reference

12 December 2020

Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines

1 reference

12 December 2020

The toxic effects of desferrioxamine

1 reference

12 December 2020

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

12 December 2020

Future of oral iron chelator deferiprone (L1)

1 reference

12 December 2020

Magnetic-susceptibility measurement of human iron stores

1 reference

12 December 2020

New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones

1 reference

12 December 2020

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

1 reference

12 December 2020

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

1 reference

12 December 2020

Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones

1 reference

12 December 2020

Effectiveness of deferiprone (L1) releasing the aluminum bound to plasma proteins in chronic renal failure

1 reference

12 December 2020

Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).

1 reference

12 December 2020

Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores

1 reference

12 December 2020

Arthropathy in thalassaemia patients receiving deferiprone

1 reference

12 December 2020

Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia

1 reference

12 December 2020

Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators

1 reference

12 December 2020

Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.

1 reference

12 December 2020

Rarity of systemic lupus erythematosus after oral iron chelator L1

1 reference

12 December 2020

Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients

1 reference

12 December 2020

Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone).

1 reference

12 December 2020

Autoantibodies in thalassaemia major: relationship with oral iron chelator L1

1 reference

12 December 2020

Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes

1 reference

12 December 2020

Deferiprone-associated myelotoxicity

1 reference

12 December 2020

Compliance assessed by the Medication Event Monitoring System

1 reference

12 December 2020

Variability in hepatic iron concentration measurement from needle-biopsy specimens

1 reference

12 December 2020

Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity

1 reference

12 December 2020

Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination.

1 reference

12 December 2020

Iron concentration and distribution in the newborn liver

1 reference

12 December 2020

Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators

1 reference

12 December 2020

Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine

1 reference

12 December 2020

Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.

1 reference

12 December 2020

The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system

1 reference

12 December 2020

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

1 reference

12 December 2020

Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels

1 reference

12 December 2020

Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies

1 reference

12 December 2020

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

1 reference

12 December 2020

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

12 December 2020

A Risk-Benefit Assessment of Iron-Chelation Therapy

1 reference

12 December 2020

Evaluation of a new method of administration of the iron chelating agent deferoxamine

1 reference

12 December 2020

Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?

1 reference

12 December 2020

Iron chelation with oral deferiprone in patients with thalassemia

1 reference

12 December 2020

Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator

1 reference

12 December 2020

Oral iron chelation with deferiprone

1 reference

12 December 2020

Uneven hepatic iron and phosphorus distribution in beta-thalassemia

1 reference

12 December 2020

Subclinical auditory and visual involvement during oral deferiprone therapy

1 reference

12 December 2020

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

1 reference

12 December 2020

Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients

1 reference

12 December 2020

Fatal systemic lupus erythematosus in patient taking oral iron chelator L1

1 reference

12 December 2020

Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia

1 reference

12 December 2020

Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients

1 reference

12 December 2020

Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

12 December 2020

Studies of an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one. I. Iron excretion in rats: development of a new rapid microwave method for iron analysis in faeces

1 reference

12 December 2020

An orally active iron chelator

1 reference

12 December 2020

Efficacy of deferiprone in the treatment of acute iron intoxication in rats

1 reference

12 December 2020

Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3.

1 reference

12 December 2020

Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial

1 reference

12 December 2020

Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro

1 reference

12 December 2020

Toxicity of oral iron chelator L1

1 reference

12 December 2020

Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia

1 reference

12 December 2020

Combined therapy with deferiprone and desferrioxamine

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload.

1 reference

12 December 2020

Iron chelators induce apoptosis in proliferating cells

1 reference

12 December 2020

Arthropathy in thalassaemia patients receiving deferiprone

1 reference

12 December 2020

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

1 reference

12 December 2020

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

1 reference

12 December 2020

A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine

1 reference

12 December 2020

A multi-center safety trial of the oral iron chelator deferiprone.

1 reference

12 December 2020

Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia

1 reference

12 December 2020

Long-term therapy with deferiprone

1 reference

12 December 2020

Iron-chelating therapy and the treatment of thalassemia.

1 reference

12 December 2020

Oxacillin-hydrolyzing β-lactamase involved in resistance to imipenem in Acinetobacter baumannii

1 reference

12 December 2020

Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease

1 reference

12 December 2020

Deferiprone in iron overload

1 reference

12 December 2020

Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone

1 reference

12 December 2020

Iron chelation therapy

1 reference

12 December 2020

Immune function in patients with β thalassaemia receiving the orally active iron‐chelating agent deferiprone

1 reference

12 December 2020

Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major

1 reference

12 December 2020

Deferiprone-Induced Agranulocytosis : A Critical Review of Five Rechallenged Cases

1 reference

12 December 2020

Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity

1 reference

12 December 2020

Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals

1 reference

12 December 2020

Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one

1 reference

12 December 2020

Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations

1 reference

12 December 2020

1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload

1 reference

12 December 2020

Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major

1 reference

12 December 2020

Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine

1 reference

12 December 2020

An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major

1 reference

12 December 2020

Iron and Atherosclerosis: Inhibition by the Iron Chelator Deferiprone (L1)

1 reference

12 December 2020

Salivary measurement of deferiprone concentrations and correlation with serum levels

1 reference

12 December 2020

Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients

1 reference

12 December 2020

Results of long-term iron-chelating therapy

1 reference

12 December 2020

10.2165/00003495-199958030-00021

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1028527442

0 references

1 reference